A novel diagnostic test from Roswell Park Cancer Institute that promises personalized treatment for cancer patients based on an analysis of their genes has received approval from the state Health Department, the cancer center announced Friday.
Scientists in Roswell Park’s Center for Personalized Medicine designed the advanced molecular diagnostic laboratory test, known as OmniSeq Target, to sort through and assess genetic data found in the tumor tissue of cancer patients.
Using the information gleaned from the test, doctors will be able to recommend a specific course of treatment for an individual patient that should allow for a better recovery, said Dr. Donald L. Trump, Roswell Park president and CEO.
The test is one of three gene-sequencing tests approved by the Health Department’s Clinical Laboratory Evaluation Program on Thursday. The test analyzes 23 genes found in a patient’s tumor sample to look for genetic abnormalities that indicate the patient would respond well to treatment using a drug that already is commercially available or a prospective medication that is being studied in a clinical trial, Trump said.
All of that data will be provided to the patient’s oncologist in a digital format, said Candace S. Johnson, Roswell Park’s deputy director, who added the test’s development was led by Dr. Carl Morrison, the Center for Personalized Medicine’s executive director.
Roswell Park initially envisions offering the test to all of the cancer center’s lung cancer patients, beginning in mid-September, before making it available to other patients in the region and, eventually, elsewhere in the country. The test soon could be expanded to colorectal cancer or malignant melanoma.